The HLA system. First of two parts.

A man dies because his body has rejected a heart transplant; a woman is crippled by rheumatoid arthritis; a child goes into a coma that is brought on by cerebral malaria; another child dies of an infection because of an immunodeficiency; an elderly man has advanced hepatic cirrhosis caused by iron overload. These five clinical situations are as diverse as can be, yet all have one thing in common: the cause of all of them involves the human leukocyte antigen (HLA) system, the human version of the major histocompatibility complex (MHC). Malfunction of the HLA system, which is at the . . .

[1]  L. Wen,et al.  In Vivo Evidence for the Contribution of Human Histocompatibility Leukocyte Antigen (Hla)-Dq Molecules to the Development of Diabetes , 2000, The Journal of experimental medicine.

[2]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[3]  A. McMichael,et al.  The arrival of HLA class II tetramers. , 1999, The Journal of clinical investigation.

[4]  Andrew W. Liu,et al.  MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. , 1999, The Journal of clinical investigation.

[5]  A. Smolyar,et al.  The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.

[6]  M. Bevan,et al.  Selecting and maintaining a diverse T-cell repertoire , 1999, Nature.

[7]  S. Forbes,et al.  The MHC quarterly report , 1999, Immunogenetics.

[8]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[9]  J. M. Boss,et al.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. , 1999, American journal of human genetics.

[10]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[11]  M. Amagai.  Autoimmunity against desmosomal cadherins in pemphigus. , 1999, Journal of dermatological science.

[12]  T. Bellón,et al.  Natural killer cell activation and inhibition by receptors for MHC class I. , 1999, Current opinion in immunology.

[13]  L. Kühn.  Iron overload: molecular clues to its cause. , 1999, Trends in biochemical sciences.

[14]  J. Goedert,et al.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.

[15]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[16]  K. Tadokoro,et al.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[17]  A. Plebani,et al.  HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. , 1999, The Journal of clinical investigation.

[18]  M. Raghavan.  Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[19]  H. Auchincloss,et al.  Direct and indirect recognition: the role of MHC antigens in graft rejection. , 1999, Immunology today.

[20]  P. Parham.  Pathways of antigen processing and presentation , 1999 .

[21]  K. Garcia,et al.  Structural basis of T cell recognition. , 1999, Annual review of immunology.

[22]  D. Garboczi,et al.  Shapes of MHC restriction. , 1999, Immunity.

[23]  M. Bachmann,et al.  Selection of the T cell repertoire. , 1999, Annual review of immunology.

[24]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[25]  D. Littman,et al.  The regulation of CD4 and CD8 coreceptor gene expression during T cell development. , 1999, Annual review of immunology.

[26]  G. Ogg,et al.  HLA-peptide tetrameric complexes. , 1998, Current opinion in immunology.

[27]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[28]  J. Frelinger,et al.  Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes , 1998, Immunological reviews.

[29]  M. Kasahara,et al.  The MHC class I ligand‐generating system: roles of immunoproteasomes and the interferon‐4gMY‐inducible proteasome activator PA28 , 1998, Immunological reviews.

[30]  A. Rudensky,et al.  Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.

[31]  M. Bogyo,et al.  A proteolytic system that compensates for loss of proteasome function , 1998, Nature.

[32]  P. Bjorkman,et al.  Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor , 1998, Cell.

[33]  A. Sato,et al.  Birth of the Major Histocompatibility Complex , 1998, Scandinavian journal of immunology.

[34]  L R Pease,et al.  Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. , 1998, Science.

[35]  D. Kwiatkowski,et al.  Association of malaria parasite population structure, HLA, and immunological antagonism. , 1998, Science.

[36]  D. M. Penny,et al.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Hill,et al.  The immunogenetics of human infectious diseases. , 1998, Annual review of immunology.

[38]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[39]  D. Roopenian,et al.  Minor histocompatibility antigens. , 1997, Current opinion in immunology.

[40]  S. Riddell,et al.  Prospects for adoptive T cell therapy. , 1997, Current opinion in immunology.

[41]  L. Jorde,et al.  Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. , 1997, American journal of human genetics.

[42]  E. Thorsby,et al.  Invited anniversary review: HLA associated diseases. , 1997, Human immunology.

[43]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[44]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[45]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[46]  Mark I. Greene,et al.  Control of MHC Restriction by TCR Vα CDR1 and CDR2 , 1996, Science.

[47]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[48]  S. Kienle,et al.  Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. , 1996, Journal of immunology.

[49]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[50]  M. Sayegh,et al.  Role of indirect allorecognition in allograft rejection. , 1996, International reviews of immunology.

[51]  T. Feltkamp,et al.  The pathogenetic role of HLA-B27. , 1996, Immunology today.

[52]  R. Karr,et al.  Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Madden.  The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[54]  D. Newton-Nash.  The molecular basis of allorecognition. Assessment of the involvement of peptide. , 1994, Human immunology.

[55]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[56]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[57]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[58]  R. Hammer,et al.  Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. , 1993, Journal of immunology.

[59]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[60]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[61]  J. Bell,et al.  The human T cell receptor in health and disease. , 1992, Annual review of immunology.

[62]  Andrew J. McMichael,et al.  Common West African HLA antigens are associated with protection from severe malaria , 1991, Nature.

[63]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[64]  A. Ahmed,et al.  Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[65]  P. Parham,et al.  Guilt by association: HLA-B27 and ankylosing spondylitis. , 1990, Immunology today.

[66]  R. Colvin.  Cellular and molecular mechanisms of allograft rejection. , 1990, Annual review of medicine.

[67]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[68]  J. Klein.  Natural history of the major histocompatibility complex , 1986 .

[69]  P. Terasaki,et al.  HLA and Disease Associations , 1985, Springer New York.